ISU
Home
ISURF/OIPTT
Home
ISURFtech
Home
Advanced
Search
RSS
Feeds
Neuroprotection by Mitochondria-targeted Metformin
Category(s):
For Information, Contact:
Dario Valenzuela
Senior Commercialization Manager, Life Sciences
515-294-4740
licensing@iastate.edu
Web Published:
12/7/2015
ISURF #
4417
Development Stage:
Description:
Metformin, a naturally-occurring biguanide, is an FDA-approved high-safety profile diabetes drug that has been used extensively for decades. Researchers at Iowa State University and Medical College of Wisconsin synthesized Mito-Met, a mitochondria-targeted analog of metformin and then evaluated the preclinical efficacy of Mito-Met in cell culture and MitoPark animal models of Parkinson’s disease. It was demonstrated that Mito-Met improved motor deficits in MitoPark mice and that it was a neuroprotective agent that exceedingly qualifies for in-depth preclinical efficacy and toxicology evaluations for treating mitochondrial diseases including Parkinson’s disease.

Advantage:
• Increases the survival of dopaminergic neurons in cell culture and in a mouse model of Parkinson’s disease
• Based on FDA-approved low-toxicity drug
• Chemical modifications increased its affinity to the intended mitochondrial target
• Addresses a high value market
• Effective at very low doses

Application:
Human Therapeutics, Treatment of Parkinson’s disease

Patent Information:
*To see the full version of the patent(s), follow the link below, then click on "Images" button.
Country Serial No. Patent No. Issued Date
United States 15/294,083 9,956,233* 5/1/2018


Direct Link: